The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of Roclanda, according to a press release from Aerie Pharmaceuticals.
Roclanda (netarsudil 0.02% and latanoprost 0.005% ophthalmic solution) would be indicated for the reduction of elevated IOP in adults with primary open-angle glaucoma or ocular hypertension for whom monotherapy provided insufficient IOP reduction.
“We are delighted that the CHMP has adopted a positive opinion for Roclanda,” Vicente Anido Jr., PhD, chairman and CEO of Aerie, said in the release. “We
Uncategorized